Summary
Edwards Lifesciences Corporation's 2015 10-K report highlights a year of significant growth, particularly driven by its Transcatheter Heart Valve Therapy (THV) segment. THV sales increased by 25.1% year-over-year, reaching $1.18 billion, largely due to the successful launches of the Edwards SAPIEN XT and SAPIEN 3 valves in key markets like the US and Europe. Despite this growth, the company's Surgical Heart Valve Therapy segment experienced a slight decline of 5.0% in net sales, impacted by foreign currency fluctuations. Overall, net sales grew by 7.4% to $2.49 billion, with net income experiencing a significant decrease of 39.0% to $494.9 million, primarily due to a substantial $750 million upfront payment received from Medtronic in 2014 as part of a litigation settlement, which boosted the prior year's net income. The company continues to invest heavily in research and development, allocating 15.4% of its net sales to drive innovation in structural heart disease and critical care. Financially, Edwards Lifesciences maintained a strong balance sheet with total assets of $4.06 billion. The company also repurchased $275 million of its common stock in 2015 and has significant capacity under its existing repurchase programs. Management's focus remains on expanding its leadership in THV, including advancements in mitral and tricuspid valve technologies, and generating robust clinical and economic evidence to support new therapies. The report also details various risk factors, including intense competition, regulatory hurdles, and potential supply chain disruptions, alongside market risks related to economic conditions and currency fluctuations.
Financial Highlights
54 data points| Revenue | $2.49B |
| Cost of Revenue | $617.20M |
| Gross Profit | $1.88B |
| R&D Expenses | $382.90M |
| SG&A Expenses | $850.70M |
| Interest Expense | $17.20M |
| Net Income | $494.90M |
| EPS (Basic) | $0.77 |
| EPS (Diluted) | $0.75 |
| Shares Outstanding (Basic) | 646.50M |
| Shares Outstanding (Diluted) | 660.90M |
Key Highlights
- 1Transcatheter Heart Valve Therapy (THV) sales grew 25.1% to $1.18 billion, driven by the SAPIEN XT and SAPIEN 3 valve launches.
- 2Total net sales increased 7.4% to $2.49 billion.
- 3Net income decreased 39.0% to $494.9 million, impacted by a large litigation settlement payment received in the prior year.
- 4Research and Development (R&D) spending was 15.4% of net sales ($383.1 million), reflecting a commitment to innovation.
- 5The company acquired CardiAQ Valve Technologies, a developer of a transcatheter mitral valve replacement system, for $350 million.
- 6The company continued its share repurchase program, repurchasing $275 million of common stock during the year.
- 7The stock price showed significant appreciation throughout 2015, ending the year at $83.43 (post-split), an increase of over 80% from the beginning of the year.